{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:30:58Z","timestamp":1746325858018},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,1,21]],"date-time":"2016-01-21T00:00:00Z","timestamp":1453334400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s00108-015-0002-x","type":"journal-article","created":{"date-parts":[[2016,1,21]],"date-time":"2016-01-21T13:12:24Z","timestamp":1453381944000},"page":"153-165","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Therapie des Typ-2-Diabetes"],"prefix":"10.1007","volume":"57","author":[{"given":"J. J.","family":"Meier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,1,21]]},"reference":[{"key":"2_CR1","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00125-014-3460-0","volume":"58","author":"SE Inzucchi","year":"2015","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB et al (2015) Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 58:429\u2013442","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"2_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP15672.GLSUPPL","volume":"21","author":"Y Handelsman","year":"2015","unstructured":"Handelsman Y, Bloomgarden ZT, Grunberger G et al (2015) American Association of Clinical Endocrinologists and American College of Endocrinology \u2013 Clinical Practice Guidelines for Developing a Diabetes Mellitus Comprehensive Care Plan \u2013 2015. Endocr Pract 21(Suppl 1):1\u201387","journal-title":"Endocr Pract"},{"key":"2_CR3","unstructured":"Abholz H-H, Egidi G, Gries FA et al (2014) Nationale VersorgungsLeitlinie Therapie des Typ-2-Diabetes, Kurzfassung 1.\u00a0Auflage, Version 4"},{"key":"2_CR4","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa1212914","volume":"369","author":"RR Wing","year":"2013","unstructured":"Wing RR, Bolin P, Brancati FL et al (2013) Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 369:145\u2013154","journal-title":"N Engl J Med"},{"key":"2_CR5","first-page":"466","volume":"109","author":"TG Breuer","year":"2012","unstructured":"Breuer TG, Meier JJ (2012) Inpatient treatment of type 2 diabetes. Dtsch Arzteblatt Int 109:466\u2013474","journal-title":"Dtsch Arzteblatt Int"},{"key":"2_CR6","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","volume":"355","author":"SE Kahn","year":"2006","unstructured":"Kahn SE, Haffner SM, Heise MA et al (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427\u20132443","journal-title":"N Engl J Med"},{"key":"2_CR7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/heart.90.1.9","volume":"90","author":"JJ Meier","year":"2004","unstructured":"Meier JJ, Gallwitz B, Schmidt WE, Mugge A, Nauck MA (2004) Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important? Heart 90:9\u201312","journal-title":"Heart"},{"key":"2_CR8","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1055\/s-0041-101365","volume":"140","author":"JJ Meier","year":"2015","unstructured":"Meier JJ (2015) Glucose-lowering therapy in patients with cardiac comorbidities. Dtsch Med Wochenschr 140:650\u2013656","journal-title":"Dtsch Med Wochenschr"},{"key":"2_CR9","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/jama.290.4.486","volume":"290","author":"JL Chiasson","year":"2003","unstructured":"Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M (2003) Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290:486\u2013494","journal-title":"JAMA"},{"key":"2_CR10","first-page":"87","volume":"7","author":"AL Peters","year":"2001","unstructured":"Peters AL (2001) Using thiazolidinediones: rosiglitazone and pioglitazone in clinical practice. Am J Manag Care 7:87\u201395","journal-title":"Am J Manag Care"},{"key":"2_CR11","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.2337\/diab.44.9.1126","volume":"44","author":"CF Deacon","year":"1995","unstructured":"Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Host JJ (1995) Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH2 terminus in type 2-diabetic patients and in healthy subjects. Diabetes 44:1126\u20131131","journal-title":"Diabetes"},{"key":"2_CR12","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1517\/13543784.13.9.1091","volume":"13","author":"CF Deacon","year":"2004","unstructured":"Deacon CF, \u00c5hren B, Holst JJ (2004) Inhibitors of dipeptidyl peptidase\u00a0IV: a novel approach for the prevention and treatment of Type 2 diabetes? Expert Opin Investig Drugs 13:1091\u20131102","journal-title":"Expert Opin Investig Drugs"},{"key":"2_CR13","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"BM Scirica","year":"2013","unstructured":"Scirica BM, Bhatt DL, Braunwald E et al (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369:1317\u20131326","journal-title":"N Engl J Med"},{"key":"2_CR14","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","volume":"373","author":"JB Green","year":"2015","unstructured":"Green JB, Bethel MA, Armstrong PW et al (2015) Effect of Sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373:232\u2013242","journal-title":"N Engl J Med"},{"key":"2_CR15","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1007\/s00125-014-3231-y","volume":"57","author":"JJ Meier","year":"2014","unstructured":"Meier JJ, Nauck MA (2014) Risk of pancreatitis in patients treated with incretin-based therapies. Diabetologia 57:1320\u20131324","journal-title":"Diabetologia"},{"key":"2_CR16","first-page":"728","volume":"8","author":"JJ Meier","year":"2012","unstructured":"Meier JJ (2012) GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nature reviews. Endocrinology 8:728\u2013742","journal-title":"Endocrinology"},{"key":"2_CR17","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.2337\/dc14-1984","volume":"38","author":"JJ Meier","year":"2015","unstructured":"Meier JJ, Rosenstock J, Hincelin-Mery A et al (2015) Contrasting effects of Lixisenatide and Liraglutide on postprandial Glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin Glargine with or without Metformin: a randomized, open-label trial. Diabetes Care 38:1263\u20131273","journal-title":"Diabetes Care"},{"issue":"5","key":"2_CR18","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/MOG.0000000000000199","volume":"31","author":"JJ Meier","year":"2015","unstructured":"Meier JJ, Giese A (2015) Diabetes associated with pancreatic diseases. Curr Opin Gastroenterol 31(5):400\u2013406","journal-title":"Curr Opin Gastroenterol"},{"key":"2_CR19","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.2337\/dc13-0387","volume":"36","author":"RA DeFronzo","year":"2013","unstructured":"DeFronzo RA, Hompesch M, Kasichayanula S et al (2013) Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care 36:3169\u20133176","journal-title":"Diabetes Care"},{"key":"2_CR20","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.2337\/dc11-0606","volume":"34","author":"MA Nauck","year":"2011","unstructured":"Nauck MA, Del Prato S, Meier JJ et al (2011) Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 34:2015\u20132022","journal-title":"Diabetes Care"},{"key":"2_CR21","author":"AL Peters","year":"2015","unstructured":"Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB (2015) Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. doi:10.2337\/dc15-0843","journal-title":"Diabetes Care"},{"key":"2_CR22","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117\u20132128","journal-title":"N Engl J Med"},{"key":"2_CR23","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1203858","volume":"367","author":"HC Gerstein","year":"2012","unstructured":"Gerstein HC, Bosch J, Dagenais GR et al (2012) Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367:319\u2013328","journal-title":"N Engl J Med"},{"key":"2_CR24","first-page":"682","volume":"371","author":"PR Schauer","year":"2014","unstructured":"Schauer PR, Bhatt DL, Kashyap SR (2014) Bariatric surgery versus intensive medical therapy for diabetes. N Engl J Med 371:682","journal-title":"N Engl J Med"},{"key":"2_CR25","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jama.2011.1914","volume":"307","author":"L Sjostrom","year":"2012","unstructured":"Sjostrom L, Peltonen M, Jacobson P et al (2012) Bariatric surgery and long-term cardiovascular events. JAMA 307:56\u201365","journal-title":"JAMA"},{"key":"2_CR26","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/oby.20066","volume":"21","author":"JE Mitchell","year":"2013","unstructured":"Mitchell JE, Crosby R, de Zwaan M et al (2013) Possible risk factors for increased suicide following bariatric surgery. Obesity (Silver Spring) 21:665\u2013672","journal-title":"Obesity (Silver Spring)"},{"key":"2_CR27","doi-asserted-by":"crossref","first-page":"e0132335","DOI":"10.1371\/journal.pone.0132335","volume":"10","author":"A Baskota","year":"2015","unstructured":"Baskota A, Li S, Dhakal N, Liu G, Tian H (2015) Bariatric surgery for type 2 diabetes mellitus in patients with BMI. PLOS One 10:e0132335","journal-title":"PLOS One"},{"key":"2_CR28","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1097\/SLA.0000000000000794","volume":"260","author":"P Koehestanie","year":"2014","unstructured":"Koehestanie P, de Jonge C, Berends FJ, Janssen IM, Bouvy ND, Greve JW (2014) The effect of the endoscopic duodenal-jejunal bypass liner on obesity and type 2 diabetes mellitus, a multicenter randomized controlled trial. Ann Surg 260:984\u2013992","journal-title":"Ann Surg"},{"key":"2_CR29","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.gie.2015.03.1911","volume":"82","author":"B Betzel","year":"2015","unstructured":"Betzel B, Koehestanie P, Aarts EO et al (2015) Safety experience with the duodenal-jejunal bypass liner: an endoscopic treatment for diabetes and obesity. Gastrointest Endosc 82:845\u2013852","journal-title":"Gastrointest Endosc"},{"key":"2_CR30","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1007\/s11695-009-9879-6","volume":"19","author":"N Crea","year":"2009","unstructured":"Crea N, Pata G, Della Casa D et al (2009) Improvement of metabolic syndrome following intragastric balloon: 1 year follow-up analysis. Obes Surg 19:1084\u20131088","journal-title":"Obes Surg"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-015-0002-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-015-0002-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-015-0002-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T04:17:41Z","timestamp":1558585061000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-015-0002-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,21]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["2"],"URL":"https:\/\/doi.org\/10.1007\/s00108-015-0002-x","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,21]]}}}